Recent Material Events - Panacos Pharm (PANC)

Filing Date	Description
2008-07-29	On July 29, 2008, Panacos Pharmaceuticals, Inc. (the “Company”) announced that the listing of its common stock, $0.01 par value per share, has been transferred from The Nasdaq Global Market to The Nasdaq Capital Market, effective with the o ...
2008-06-17	On June 17, 2008, Panacos Pharmaceuticals, Inc. issued a press release announcing the results of a Phase 2b prospective study of bevirimat, which confirm the recently discovered factors that predict patient response to bevirimat. A copy of the press ...
2008-06-11	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2008-01-07	(c) On January 7, 2008, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced the appointment of Jane Pritchett Henderson, age 42, as the Company’s Executive Vice President, Chief Financial Officer, Chief Busin ...
2008-01-03	Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ...
2007-09-25	10.1 Separation Agreement by and between the Company and Dr. Marshall, dated as of September 21, 2007. ...
2007-08-31	The information in this Form 8-K related to the 20th Annual Bear Stearns Healthcare Conference and Dr. Dunton’s presentation shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the ...
2007-03-12	On March 12, 2007, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) issued a press release announcing its bevirimat phase 2b dose escalation strategy and additional information regarding the next phase 2b cohort. A copy... ...
2007-02-21	Also in our press release dated February 21, 2007, we provided an update on the status of the first bevirimat Phase 2b cohort. A copy of the press release is filed herewith as Exhibit 99.1. Solely the information contained therein updating the status... ...
2007-01-09	(c) On January 8, 2007, Panacos Pharmaceuticals, Inc. (“Panacos” or the “Company”) announced that Alan W. Dunton, M.D., age 52, was appointed by the Board of Directors to be the Company’s Chief Executive Officer as of January... ...